Table II.

SLC increases the frequency of CD4+ and CD8+ lymphocyte subsets secreting IFN-γ and GM-CSF and CD11c + DEC205-expressing DCa

GroupsCD4+CD8+
IFN-γGM-CSFIFN-γGM-CSFCD11c + DEC205
%MCF%MCF%MCF%MCF%MCF
Tumor
3LL3.6193 >4.831 >1.93891.744 >4 >103 >
3LL+ SLC7.4*1875.352*3.2*3062.7*4713*108
LN
3LL0.9860.8500.91910.5783279
3LL+ SLC1.7*340*1.2*181*1.7*1811.3*107*40*118*
  • a Single-cell suspensions of tumor nodules and lymph nodes from SLC and diluent-treated tumor-bearing mice were prepared. Intracytoplasmic staining for GM-CSF and IFN-γ and cell surface staining for CD4 and CD8 T lymphocytes were evaluated by flow cytometry. DC that stained positively for cell surface markers CD11c and DEC205 in lymph node and tumor nodule single-cell suspensions were also evaluated. Cells were identified as lymphocytes or DC by gating based on the forward and side scatter profiles; 15,000 gated events were collected and analyzed using Cell Quest software. Within the gated T lymphocyte population, intratumoral injection of SLC led to an increase in the frequency of CD4+ and CD8+ cells secreting GM-CSF and IFN-γ in the tumor nodules and lymph nodes compared with those of diluent-treated tumor-bearing control mice. Within the gated DC population, there was a significant increase in the frequency of DC in the SLC-treated tumor-bearing mice compared with the diluent-treated control tumor-bearing mice. For DC staining, MCF is for DEC205. MCF, mean channel fluorescence. Experiments were repeated twice.

  • b , p < 0.01 (n = 6 mice/group).